Joint presentation to discuss the implications of moving cannabis from schedule I to schedule III.
Will cover issues such as the current status of the rescheduling, impacts on businesses currently engaged in the development of cannabis-derived products, and changes to regulatory oversight resulting from rescheduling.
Will explore specific scenarios where rescheduling affects the sale and development of all cannabis-derived products, including products currently legally on the market under the 2018 Farm Bill.
What you will learn:
• Rescheduling process: What to expect and when to expect it.
• How rescheduling will change the current market for medicinal and recreational cannabis products.
• How rescheduling will impact FDA regulation of cannabis companies and their products, including delta-9-THC, delta-8-THC, THCA, CBD, and synthetic cannabinoids.